An integrated care pathway improves quality of life in Primary Biliary Cirrhosis

被引:42
作者
Jones, David E. J.
Sutcliffe, Katy
Pairman, Jessie
Wilton, Katharine
Newton, Julia L. [1 ]
机构
[1] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
[2] Newcastle Univ, Reg Primary Biliary Cirrhosis, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
[3] Newcastle Hosp NHS Trust, Newcastle Upon Tyne, Tyne & Wear, England
基金
英国医学研究理事会;
关键词
D O I
10.1093/qjmed/hcn043
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Clinical management of the chronic autoimmune liver disease, Primary Biliary Cirrhosis (PBC) involves addressing the underlying liver disease and a range of symptoms independent of liver disease severity. We have formally explored how these two perspectives of chronic disease management can be combined into a clinic consultation and impact upon quality of life (QOL) in PBC. Aims: To develop and implement the first Integrated Care Pathway (ICP) for the management of liver disease progression and symptom management in PBC. Methods: Process mapping of current practice by a multidisciplinary group developed a flowchart of care from which the clinical record evolved. Symptom assessment is incorporated into the PBC ICP (QOL; PBC-40, autonomic symptoms; Orthostatic Grading Scale, daytime sleepiness; Epworth Sleepiness Scale). All patients were considered who attended clinic between July 2005 and June 2006. Symptom assessment was repeated after 1 year in those participating in the initial clinic cohort. Results: The PBC ICP was successfully introduced into our clinical environment with high levels of patient satisfaction. A total of 225 PBC patients attended over 12 months. Initial QOL assessments were in 195 (87). Five patients died (3). Repeat assessment 1 year later occurred in 149 subjects (149/190; 78). All symptom domains improved after ICP implementation with significant improvements in those with moderate and severe symptoms in all PBC-40 symptom domains (P < 0.02). In those with severe fatigue (n = 38) symptom improvement was even more dramatic (P = 0.002). Conclusion: ICP implementation delivers evidence-based care, leads to improvements in QOL coupled with high levels of patient satisfaction.
引用
收藏
页码:535 / 543
页数:9
相关论文
共 23 条
[1]   Fatigue in primary biliary cirrhosis [J].
Cauch-Dudek, K ;
Abbey, S ;
Stewart, DE ;
Heathcote, EJ .
GUT, 1998, 43 (05) :705-710
[2]   The true impact of fatigue in primary biliary cirrhosis: A population study [J].
Goldblatt, J ;
Taylor, PJS ;
Lipman, T ;
Prince, MI ;
Baragiotta, A ;
Bassendine, MF ;
James, OFW ;
Jones, DEJ .
GASTROENTEROLOGY, 2002, 122 (05) :1235-1241
[3]  
Huet PM, 2000, AM J GASTROENTEROL, V95, P760
[4]   Development, validation, and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis [J].
Jacoby, A ;
Rannard, A ;
Buck, D ;
Bhala, N ;
Newton, JL ;
James, OFW ;
Jones, DEJ .
GUT, 2005, 54 (11) :1622-1629
[5]   Primary biliary cirrhosis once rare, now common in the United Kingdom? [J].
James, OFW ;
Bhopal, R ;
Howel, D ;
Gray, J ;
Burt, AD ;
Metcalf, JV .
HEPATOLOGY, 1999, 30 (02) :390-394
[6]   SLEEPINESS IN DIFFERENT SITUATIONS MEASURED BY THE EPWORTH SLEEPINESS SCALE [J].
JOHNS, MW .
SLEEP, 1994, 17 (08) :703-710
[7]  
Johnson S, 2000, Prof Nurse, V15, P640
[8]   An open study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis [J].
Jones, D. E. J. ;
Newton, J. L. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 25 (04) :471-476
[9]  
JONES DEJ, 2005, HORIZONS MED, V17
[10]   Modafinil for the treatment of fatigue in primary biliary cirrhosis [J].
Kaplan, MM ;
Bonis, PAL .
ANNALS OF INTERNAL MEDICINE, 2005, 143 (07) :546-547